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Penetrating peptides are unique peptides that can translocate across membranes in a non-
lytic fashion. A new class of penetrating peptides that can target the mitochondria with high 
specificity have been developed. Targeting the mitochondria is therapeutically valuable, given 
the organelle’s role in energy production and apoptosis. The peptide we studied is sufficiently 
cationic and hydrophobic and is hypothesized to reach the mitochondrial matrix.2 However, the 
mechanism of translocation remains unknown. In our work, we use solid state NMR to gain 
insight into the mechanism of translocation of this mitochondria-penetrating peptide. We use 
static 31P NMR the membrane morphology and peptide-induced structure changes. The 
paramagnetic relaxation effect examined through 13C MAS NMR3 was used for insertion depth 
determination and to distinguish bilayer sidedness. We found that the peptide does not disrupt 
the lamellarity. Also, at low peptide concentrations the peptide binds to the outer leaflet and at 
high concentrations crosses the hydrophobic bilayer core and is distributed in both leaflets. Our 
findings support the electroporation model of translocation, but we did not observe complete 
translocation of the peptide.  We examine the energy associated with crossing the inner 
mitochondrial membrane to determine the feasibility of the peptide reaching the mitochondrial 
matrix. 
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1.0  INTRODUCTION 
One of the main problems of therapeutic efficiency is the inability of drugs to cross cellular 
membranes.1 Therefore, a significant effort has been made to develop a method to allow drugs to 
cross lipid bilayers without lysing the cell.1 Cell-penetrating peptides (CPPs) are peptides that 
can cross membranes in a non-lytic fashion and carry attached cargo inside the cell.2 Once 
inside, the therapeutic cargo is cleaved from the peptide and can reach its appropriate target. 
These short protein transduction domains (<30 amino acids) typically consist of a combination of 
hydrophobic residues and basic, charged residues such as arginine and lysine.2 Because of the 
efficient cellular uptake and low toxicity associated with these peptides, they are the ideal 
candidate to deliver therapeutics and are beginning to be applied in the medical field.1 However, 
some weaknesses are still present, in particular, the lack of specificity towards the intended 
target.1  
Several organelles within the cell are useful targets. From protein folding, to processing 
genetic information, to programmed cell death, each organelle plays a specific role. In order to 
gain access to specific organelles, it is essential to identify the properties that make an efficient 
penetrating peptide to tailor its selectivity towards different locations.1 To accomplish this, it 
would be helpful to elucidate the mechanism of translocation, which remains largely unknown.3-4 
A variety of mechanisms have been proposed and are generally divided into two categories: 
endocytosis or direct translocation (Figure 1).5 Endocytosis routes include macropinocytosis and 
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clathrin- and caveolin-independent endocytosis.6 Endocytosis is an energy-dependent mechanism 
in which the peptide in the extracellular environment is encapsulated into a lipid vesicle and 
internalized after resealing the plasma membrane. 
However, due to the potential dependence and preservation of bilayer, penetrating 
peptides are believed to proceed by direct translocation. The possible mechanisms of direct 
translocation include electroporation,7-9 inverse micelles,10-12 and guanidinium-phosphate 
mediated translocation.13 In the first model,11 inverse micelles transiently form in the bilayer to 
trap the peptide from the extracellular environment and release it into the cytosol. In the second 
model,13 a guanidinium-phosphate complexation neutralizes the cationic residues of the peptide 
and allows the peptides to cross the hydrophobic core of the bilayer without a high free-energy 
penalty. In the electroporation model,7 at low peptide concentrations the peptide binds to the 
outer leaflet of the bilayer where the cationic residues can interact with the phosphate 
headgroups. If the bilayer is anionic, the accumulation of positively charged residues attracts 
negatively charged lipids, which induces an electric field until a threshold is reached where 
transient pores are formed.8 Therefore, at high peptide concentration, electroporation 
permeability allows the peptide to cross to the inner leaflet where it can be released into the 
cytosol. Due to the diversity of orangellar membranes, it is plausible that the mechanism varies 
for each individual target. 
 3 
 
E
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Guanidinium - Phosphate
Electroporation
Macropinocytosis
DIRECT TRANSLOCATION
ENDOCYTOSIS
Figure 1. Proposed mechanisms used by penetrating peptides to cross membranes. Image adapted from Sebbage, 
et al.
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A target of particular interest is the mitochondria, due to its role in apoptosis and energy 
production and subsequently, disease.14-20 Mitochondrial defects have been attributed to several 
conditions such as cancer,21-22 hypothyroidism,23-25 heart disease,26-28 and genetic diseases such 
as MELAS syndrome.29 Unfortunately, targeting the mitochondria has proven difficult due to the 
intricacies involved in crossing three membranes: the plasma membrane, along with both the 
outer and inner mitochondrial membranes (OMM and IMM, respectively) to reach the matrix 
where energy production and apoptosis take place (Figure 2).18   
The most difficult barrier to gain access to the matrix is the IMM, which differs 
significantly from almost all other eukaryotic plasma membranes. In the past, this organelle has 
been inaccessible by targeted drugs due to the following properties, hindering treatment of 
mitochondrial diseases.14-15,17 The IMM has a transmembrane electrochemical potential (∆ψ) of -
180 mV (negative inside), much greater than the transmembrane potential across the plasma 
membrane of -60 mV.18 Furthermore, the “signature lipid of mitochondria” is cardiolipin.18 
Cardiolipin is rarely found in other lipid membranes and is a unique phospholipid in that the 
headgroup is tailored to support four fatty acid tails instead of two.18 Due to the prevalence of 
cardiolipin surrounding protein complexes in the electron transport chain embedded in the IMM, 
it is believed to be essential for the assembly of these complexes or necessary to maintain their 
functional conformation by acting as a proton trap.18 This theory is supported by experiments in 
which the biosynthesis of cardiolipin was inhibited, resulting in mitochondrial defects in 
respiration.18 Due to the fact that cardiolipin restricts the permeability of even protons, gaining 
access to this organelle has proven especially difficult. 
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Δψ = -180 mV
Δψ = -60 mV
Cell membrane
Inner mitochondrial
membrane
Figure 2. Membrane barriers encountered by mitochondria-penetrating peptides. Cell penetrating peptides only cross 
the plasma membrane. Mitochondria-penetrating peptides must cross a total of three membrane barriers; the plasma 
membrane, the OMM, and the IMM. The IMM is the least permeable barrier, with the dense bilayer structure. 
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In spite of these difficulties, the Kelley group at the University of Toronto was able to 
design and synthesize a group of peptides that exhibited mitochondrial penetrating properties.16  
Not only are the mitochondria-penetrating peptides (MPPs) able to cross the plasma membrane, 
once in the cytosol they are able to localize in the mitochondria.16 MPP uptake and localization 
was analyzed in a variety of human cell lines by flow cytometry and confocal fluorescence 
microscopy.16 By conjugating the MPPs to a fluorophore and comparing with Mitotracker 
CMXRos (a fluorophore known to localize in the mitochondria), the fluorescence images 
provided relative mitochondrial specificity.16  
The Kelley group also examined different mechanisms of internalization. They found that 
endocytosis inhibitors did not alter the localization, so an energy-dependent mechanism was 
ruled out.16 Also, when the transmembrane potential was depleted the MPP uptake decreased.16 
Similarily, when the transmembrane gradient was larger, the MPP uptake was enhanced.16 These 
results indicate that MPPs localize in the mitochondria by direct potential-driven diffusion, but 
the exact mechanism remains unknown.16 It is also difficult to determine the exact suborganellar 
location of the MPPs.16 Due to the resolution limit of confocal microscopy, the outer and inner 
membranes cannot be resolved and it is impossible to determine whether the MPPs actually 
reach the matrix.16 
To achieve atomic-scale resolution, we have used a solid state nuclear magnetic 
resonance (ssNMR) technique. For our study, we chose a peptide with high mitochondrial 
localization and the amino acid sequence Cha – Arg – Cha – Lys, where Cha = 
cyclohexylalanine.16 With ssNMR we wanted to examine the presence of peptide-induced 
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changes in membrane structure and morphology. We also used this method to determine the 
peptide location in our system during translocation.  
Model membrane systems are advantageous for research purposes because they 
accurately mimic biological membranes.30 With model membranes, we can focus on peptide-
lipid interactions and eliminate the complexities present in biological cells, such as 
carbohydrates and proteins.  In order to make a bilayer system that accurately models the IMM, 
we needed a complex lipid mixture. As with any other membrane, the composition of the IMM 
varies with respect to tissue type and organism. Three major phospholipids (Table 1) are always 
present in the IMM at the following percentages: cardiolipin (10-20%), 
phosphatidylethanolamine (20-40%), and phosphatidylcholine (35-50%).18 Other phospholipids, 
such as phosphatidylinositol are generally only present at approximately 5% of total lipid 
composition along with trace amounts of cholesterol.18 For this reason, other phospholipids and 
cholesterol were not part of the composition for the model membrane systems. We used a lipid 
mixture of 10 mol% cardiolipin, 50 mol% phosphatidylcholine, and 40 mol% 
phosphatidylethanolamine (Table 1, Figure 3) 
Several systems have been developed to model lipid membranes: supported lipid bilayers 
(SLBs),31 multilamellar vesicles (MLVs),32 and giant, large, and small unilamellar vesicles 
(GUVs,33 LUVs,34 and SUVs35). For the present study, large unilamellar vesicles were chosen as 
the model system because they are unilamellar, highly stable,36 and can be studied with ease 
using ssNMR. Examination of the orientation and insertion, lipid interaction, and oligomeric 
structure in similar experiments has led to conclusions about the mechanism of different classes 
of penetrating peptides.37 
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Table 1. Lipid composition of the inner mitochondrial membrane and our models. 
Lipid Inner mitochondrial membrane Our model membranes 
Cardiolipin (CL) 10-20% 10% 
Phosphatidylcholine (PC) 35-50% 50% 
Phosphatidylethanolamine (PE) 20-40% 40% 
Phosphatidylinositol (PI) 5% None 
Cholesterol Trace amounts None 
(a)
(b)
(c)
Figure 3. Chemical structures of lipids. (a) Cardiolipin 18:1, (b) Phosphatidylcholine 16:0-18:2, (c) 
Phosphatidylethanolamine 18:0. 
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Solid-state NMR (ssNMR) offers the ability to look at MPPs in the lipid bilayer where 
the mechanism of translocation can be revealed. With ssNMR, we can observe chemical shift 
anisotropy (CSA) of the phospholipid head groups.38 The magnitude of the chemical shift will 
vary as a function of molecular orientation with respect to the magnetic field, which results in the 
CSA.38  The chemical shift tensor is expressed in a coordinate frame where the off-diagonal 
components vanish and only the principal axis system is left.38 The chemical shift tensor is then 
described by the principal components: δ11, δ22, and δ33 (Figure 4).
38-39 The relative isotropic 
value associated with these chemical shift tensors is the average of the three: 
 
In this system, the principal component δ11 corresponds to the direction of least shielding and 
highest frequency, while δ33 corresponds to the direction of highest shielding and lowest 
frequency.40 The anisotropic part of the chemical shift frequency for an axially symmetric 
shielding tensor is 
 
where Δ is the CSA.38,41 For the non-axially symmetric case, the chemical shift frequency can be 
expressed in terms of the isotropic component, shielding anisotropy, and asymmetry (ε): 
 
where –ω0δiso = ωiso is the isotropic chemical shift frequency, relative to the Larmor frequency, 
ω0.
41 
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δ11
δ11
δ22
δ22
δ33
δ33
δiso
Figure 4. The 
31
P chemical shift anisotropy of unoriented static phospholipids and the associated chemical shift 
tensors.
39
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Mechanism NMR Experiment Expected results 
Endocytosis Static 
31
P NMR Changes in 
31
P CSA, isotropic peaks 
Inverse micelles Static 
31
P NMR Isotropic 
31
P peak in CSA 
Guanidinium - 
Phosphate 
PRE 
13
C MAS NMR High signal intensity in one side Mn
2+
 bound samples and 
low signal intensity for two side Mn
2+
 bound samples at all 
peptide concentrations. 
Electroporation PRE 
13
C MAS NMR High signal intensity in one side Mn
2+
 bound samples and 
low signal intensity for two side Mn
2+
 bound samples at 
high peptide concentrations.  No change in signal intensity 
between one and two side bound samples at low peptide 
concentration. 
Table 2. The expected NMR results associated with each mechanism of translocation. 
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In an unoriented, large unilamellar vesicle system, all molecular orientations are present, 
so we expect to see a powder pattern (Figure 4).41 In our sample, the shielding principal axis 
frame is fixed in the molecule so all values of the angle ζ, and φ in non-axial symmetry, are 
possible.41 Each molecular orientation possesses a different orientation on the principal axis 
frame with respect to the magnetic field, so each has a different chemical shift.41 The peaks from 
the different orientations overlap and form a continuous line shape. Some orientations have the 
same chemical shift, so the resulting intensity at any given frequency in a powder pattern 
reflections the number of orientations with the same chemical shift.41 This gives the powder 
pattern a distinct shape which depends on the symmetry at each nucleus. 
In our system, static 31P CSA can be used to observe how the phospholipid headgroups 
change when bound to the MPP. If the peptide is causing lipid rearrangement, such as 
endocytosis or inverse micelles, changes in the 31P chemical shift anisotropy would be expected 
(Table 2).42 Herein, we present a variable temperature study which examines the powder pattern 
resulting from the 31P CSA of the both the unbound and MPP bound membrane. 
The development of magic angle spinning (MAS) and specialized 2D pulse sequences 
has led to high resolution spectra, comparable with solution state NMR, which can provide 
details on the structure and dynamics of a variety of biomolecules.38,43-44 By spinning at the 
magic angle of 54.74°, the dipolar coupling quantity in the spin NMR Hamiltonian is reduced to 
zero, eliminating the anisotropic solid state interactions.43-44 We use MAS to probe molecular 
details of our membrane bound MPP system. We use isotropic 13C chemical shift to determine 
insertion depth.13,45  
 13 
Paramagnetic relaxation enhancement (PRE) experiments were performed to determine 
which leaflet of the bilayer the MPP interacts and depth of insertion. These properties were 
investigated by using a 13C MAS NMR PRE method described by the Hong group.13 
Paramagnetic ions are able to bind to membranes and cause line broadening and signal decrease 
in NMR spectra by enhancing the T2 relaxation rate.
13 Due to the fact that Mn2+ ions cannot 
penetrate the hydrophobic portion of the bilayer, this PRE effect is distance dependent.46 The 
paramagnetic contribution to dipolar transverse relaxation depends on the average electron – 
nucleus distance (r) according to the following equation45: 
 
where the correlation time τs is the inverse sum of the electronic spin-lattice relaxation time T1e, 
the rotational correlation time of the molecule τr, and the residence time of the Mn
2+ near the 
nuclear spin τm
45: 
 
In the first equation, W is the local concentration of Mn2+ ions, γc is the gyromagnetic ratio of the 
13C spin, µ0 is the vacuum permeability, µeff is the effective magnetic moment of Mn
2+ ions, β is 
the Bohr magneton, ωc is the 
13C Larmor frequency, and ωe is the electron Larmor frequency.
45 
From these equations we can see that the signal attenuation due to the paramagnetic ions is 
distance dependent. 
In this experiment, we can compare the peptide and lipid signal attenuation to determine 
bilayer sidedness and depth of insertion. For example, a peptide present only in the outer leaflet 
should have little intensity change between the one side and two side Mn2+ bound membranes.13 
 14 
On the other hand, a peptide inserted in both the inner and outer leaflet should have an intensity 
decrease from one side to two side Mn2+ bound samples (Figure 5).13 By gaining information on 
the peptide location in the bilayer we can make conclusions about the mechanism of 
translocation (Table 2).  
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Mn2+ Mn2+ Mn2+ Mn2+ Mn2+ Mn2+
out
in
Low intensity High intensity
Figure 5. Paramagnetic relaxation effect of Mn
2+
 on peptides in lipid bilayers. Peptide bound to only the outer 
leaflet will exhibit low NMR intensity in the one side Mn
2+
 bound sample (left). Peptide bound to both bilayers 
will retain high intensity from peptide signals from the inner leaflet unaffected by the one side nature of Mn
2+
 
(right). 
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2.0  MATERIALS AND METHODS 
Lipids and Peptides 
All lipid products used to form the model mitochondrial membranes are commercially available, 
including 1,1',2,2'-tetraoleoyl cardiolipin sodium salt (18:1 CL), 1-palmitoyl-2-linoleoyl-sn-
glycero-3-phosphocholine (16:0-18:2 PC), and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine 
(18:0 PE), and were purchased from Avanti Polar Lipids, Inc. (Alabaster, AL) and used without 
further purification. The MPP under investigation (Cha – Arg – Cha – Lys) was purchased from 
AnaSpec, Inc. (Freemont, CA) with uniformly labeled 13C, 15N residues at positions R2 and K4 
at > 95% purity. Unlabeled peptide was also purchased from GenScript Corporation (Piscataway, 
NJ). All other chemicals were purchased from Thermo Fisher Scientific (Pittsburgh, PA) and 
used as received. 
Large Unilamellar Vesicles 
Hydrated CL/PC/PE membranes were formed by dissolving the lipids in chloroform or a 95:5 
benzene:ethanol mixture at an appropriate molar ratio of 0.1/0.5/0.4, respectively. The lipid 
mixture was dried under a stream of nitrogen gas and placed on a vacuum pump overnight to 
remove residual solvent when chloroform was used, or lyophilized overnight when the 
benzene:ethanol mixture was used. The dried lipid cake was rehydrated with a suitable buffer, 
 17 
either 10 mM acetate buffer at pH 6 or 10 mM phosphate buffer at pH 7 and heated to 85°C. The 
particular buffer composition was used to avoid interference in the 13C and 31P NMR signals, 
respectively. The rehydrated lipid sample was incubated for 2 hours at 85°C and vortexed 
periodically to produce MLVs. The sample was heated to 85°C so that extrusion was performed 
above the highest transition temperature, Tm, of the lipid mixture. The resulting MLVs were 
converted to LUVs using a mini extruder (Avanti Polar Lipids, Inc.) and passed through a 100 
nm polycarbonate membrane 21 times to produce homogeneous vesicles with a diameter of 100 
nm. The size of the vesicles was validated by dynamic light scattering on a ZetaPALS particle 
size analyzer. From this point forward, the LUVs were kept at 37°C to maintain a 
physiologically relevant temperature. The MPP was added to the LUV solution and incubated 
overnight. The LUVs were centrifuged at 150 000g for 2.5 hours to yield a hydrated membrane 
pellet, which was packed into a 200 µL MAS rotor. 
Some of the experiments also incorporated Mn2+ as a paramagnetic relaxation 
enhancement agent. For these samples, the Mn2+ solution was prepared from MnCl2·4H2O and 
added at 8 mol% of the lipids. To obtain one side Mn2+ bound vesicles, the Mn2+ solution was 
added after ultracentrifugation, typically directly to the rotor containing unbound vesicles. The 
one side Mn2+ bound vesicles were freeze-thawed 8-10 times, creating MLVs with Mn2+ on both 
sides.13 
LUVs Exhibiting a Transmembrane Potential 
In an attempt to more accurately model mitochondrial membranes, we constructed LUVs with a 
transmembrane gradient following a protocol developed by the Hope group.47 The Hope protocol 
states that by entrapping high buffer concentration in LUVs, a negative gradient can be formed 
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across the membrane by having an acidic pH inside and a neutral pH outside.47 Membranes are 
extremely permeable to H+ ions, but this process is self limiting because the efflux of H+ also 
sets up a positive electrical potential outside of the membrane, which inhibits H+ ions from 
leaving the interior.47 At equilibrium, the potential of the membrane will follow the Nernst 
equation: 
 
Therefore, if the membrane is constructed with pH 4 inside and pH 7 outside, the membrane will 
exhibit an electrochemical potential of -177 mV,47 which is close to the true mitochondrial 
gradient of -180 mV.18 The existence of a three unit pH gradient in our system was confirmed by 
the fluorescence response of 9-aminoacridine as described by Casadio and Melandri.48 
Hydrated membrane samples were formed as previously described with a few minor 
changes to establish the gradient. For example, the lipid cake was rehydrated with 300 mM 
phosphate buffer at pH 4 to ensure the stability of the gradient and produce an acidic interior. 
The rehydrated sample was extruded in the same manner. However, after extrusion, the LUVs 
were dialyzed overnight using a Slide-A-Lyzer (Thermo Fisher Scientific) to remove the higher 
density, more acidic buffer and replace it with 10 mM phosphate buffer at pH 7 for the exterior 
membrane environment. In MPP incorporated samples, the peptide was added after dialysis and 
ultracentrifuged. All other experimental parameters and consequent steps were the same as 
previously described in Section 2.1.3. 
To produce one side Mn2+ bound vesicles, the lipids were extruded with 8 mol% Mn2+ 
and then dialyzed, resulting in vesicles with Mn2+ bound to only the inner leaflet. To produce 
two side Mn2+ bound vesicles and maintain the gradient, the freeze-thaw method could not be 
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used. This procedure disrupts the unilamellar lipid bilayer by reassembling the lipids through ice 
formation. Therefore, the vesicles with Mn2+ bound to only the inner leaflet had 4 mol% Mn2+ 
added to the membrane pellet to produce two side Mn2+ bound LUVs. 
NMR Spectroscopy 
All NMR measurements were carried out on a Bruker Avance 500 (11.7 T) spectrometer at a 
resonance frequency of 500 MHz for 1H, 200 MHz for 31P, 125 MHz for 13C, equipped with a 
BCU05 Variable Temperature Control Unit. Data was processed using Bruker Topspin 1.3 or 
iNMR software. All sample rotors were Bruker 4 mm ZrO2 magic angle spinning (MAS) rotors 
with internal volumes of 12 µL, 50 µL, or 200 µL. All experiments were performed using a 
Bruker HXY broadband MAS probehead doubly tuned to 1H/13C/Y or 1H/31P/Y. 13C chemical 
shifts were externally referenced to adamantane at 38.5 ppm on the TMS scale. 31P chemical 
shifts were referenced to 85% phosphoric acid at 0.0 ppm. The spinning rate for MAS 
experiments was 5 kHz. 
Static 31P spectra were decoupled with WALTZ-16 at 1H field strengths of 6 kHz. 
Typical radiofrequency (rf) pulse lengths were 4 µs for 31P and 1-2 µs for 1H. A minimum of 
1200 scans were collected, each consisting of 4096 complex data points.  31P spectra were 
acquired using an inverse-gated pulse sequence. The acquisition time was 68 ms, spectral width 
was 30 kHz, the recycle delay was 3 s, and the sample volume was 50 µL. 
13C direct polarization MAS NMR spectra were decoupled with two pulse phase 
modulation (TPPM) at 1H field strengths of 30 kHz. Typical radiofrequency (rf) pulse lengths 
were ~5 µs for 13C and 1-2 µs for 1H. A minimum of 6144 scans were collected, each consisting 
of 8192 complex data points.  13C spectra were acquired using an inverse-gated pulse sequence 
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for direct polarization. The acquisition time was 41 ms, spectral width was 50 kHz, the recycle 
delay was 8 s, and the sample volume was 200 µL. 
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3.0  RESULTS AND DISCUSSION 
Membrane Morphology in the Presence of Peptide 
Static 31P NMR spectra show the chemical shift anisotropy (CSA) of solids and can provide 
information on the structure and phase behavior of phospholipid headgroups. In this experiment, 
we vary the temperature over a wide range from 280 K – 360 K (the highest phase transition 
temperature of the lipid mixture is 347 K). First, a series of variable temperature experiments 
were collected for the CL/PC/PE LUVs in the absence of peptide to ascertain the behavior of the 
pure membranes. These results are compared in Figure 6 to MPP-containing membranes with a 
high peptide to lipid ratio of 1:12.5. If the MPP is perturbing the dynamics of the membrane, it 
would be apparent at high peptide to lipid ratios. However, in all spectra, we observed a powder 
pattern, characteristic of undisrupted, unoriented LUVs. The lack of an isotropic signal at 0 ppm 
rules out the possibility of inverse micelles shuttling the peptide into the cell. 
Overall, from this data, we were able to conclude that aside from extremely small 
differences, the 31P CSAs show generally the same powder pattern in the presence of the MPP. 
Also, the same spectra are observed before and after the phase transition. This indicates that the 
peptide does not alter the phase behavior of the lipids or cause membrane disruption. Therefore, 
the MPP most likely does not translocate via an energy dependent mechanism, such as 
 22 
endocytosis. This observation is consistent with the theory that MPPs translocate without 
damaging the integrity of the membrane.  
 23 
 
Figure 6. The peptide does dramatically alter the structure of the membrane. Static 
31
P NMR spectra of liposomes (a) in the 
absence of MPP and (b) in the presence of MPP. 
360 K
340 K
320 K
300 K
280 K
360 K
340 K
320 K
300 K
280 K
31P Chemical Shift (ppm)
+MPP
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Location of Peptide in the Bilayer 
Since preliminary evidence suggested a mechanism of direct translocation for the MPP, we 
decided to test the hypothesis of electroporation by PRE with Mn2+ to determine the depth of 
insertion. First, we had to establish that our lipid membrane system could confine paramagnetic 
ions to one side of the bilayer for asymmetric measurements.  In order to confirm the one sided 
binding of Mn2+ to CL/PC/PE LUVs, static 31P NMR spectroscopy was performed to examine 
the dephasing of the headgroups in absence of the MPP. The results are shown in Figure 7 and 
the one side Mn2+ samples show dephasing of 47%, which is reasonable; approximately half of 
the lipid headgroups from the inner leaflet are not affected by the PRE. As expected, the 31P 
signal is completely dephased for the two side Mn2+ bound samples. 
 After verifying the one and two side Mn2+ distribution across the bilayer, the feasibility 
of using gradient vesicles was examined. To begin, the MPP was added to both non-gradient and 
gradient (Δψ = -177 mV) vesicles at a peptide-to-lipid ratio of P:L = 1:40 and probed with 13C 
direct polarization MAS NMR. In order to compare between different samples, the peak intensity 
was double-normalized, (S/S0)/(S/S0)max where S is the signal intensity of the Mn
2+ bound 
sample, S0 is the signal intensity of the unbound reference sample, and (S/S0)max is the 
normalized value of the lipid peak with the least attenuation. The maximum value typically fell 
between the methyl group at the end of the acyl chain (ω) and the CH2 groups because they are 
embedded in the center of the bilayer and experience the least PRE. 
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Figure 7. Manganese ions do not cross the bilayer and form stable one side bound samples. Static 
31
P NMR spectra of 
(a) unbound, (b) one side Mn
2+
 bound with 47% dephasing, and (c) two side Mn
2+
 bound with 100% dephasing 
CL/PC/PE LUVs. 
31P Chemical Shift (ppm)
(a)
(a)
(b)
(b)
(c)
(c)
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 According to our results, the lipid peaks are attenuated as expected for all samples. In the 
one side Mn2+ bound samples, much of the signal intensity from the acyl chain is retained at 80 – 
100% until C2. At this point, the signal becomes dephased significantly at approximately 40% 
from C1 through the glycerol and choline peaks. In the two side Mn2+ bound samples, the 
dephasing decreases even more in this region to 0-25%. Upon comparison of the gradient and 
non-gradient vesicles, nearly identical spectra were observed. As shown in Figure 8, the MPP is 
only distributed on the outer leaflet of the bilayer and at the same insertion depth between both 
samples. Therefore, we can conclude that the LUVs exhibiting a gradient of -177 mV are a 
reliable model to assess the mechanism of MPPs. 
 To investigate the electroporation model, the MPP was added to the gradient LUVs at 
both low (P:L = 1:40) and high (1:10) concentrations. Figure 9a-b shows that at P:L = 1:40, the 
peptide peaks have the same low intensity in the one and two side Mn2+ bound samples. This 
result is indicative of the MPP binding to only the outer leaflet of the bilayer. When the peptide-
to-lipid ratio is increased to P:L = 1:10, the peptide peaks experience greater attenuation in the 
two side Mn2+ bound sample (Figure 9d) as compared to the one side Mn2+ bound sample 
(Figure 9c). Therefore, at this ratio the peptide is bound to both the inner and outer leaflet of the 
bilayer. In the one side Mn2+ bound experiment, only half of the MPP is experiencing dephasing 
due to the PRE, thus maintaining most of its signal intensity. However, in the two side Mn2+ 
bound sample, all of the peptides are subjected to the PRE, resulting in a decrease in intensity as 
shown by the fractions of intensity indicated below the peptide peaks. Figure 10 shows a 
graphical representation of the PRE effect on the normalized signal intensity. At low P:L = 1:40, 
there is no change in signal intensity when comparing one side and two side Mn2+ bound 
membranes. At high P:L = 1:10, the peptide retains much of its signal intensity (about 80%) in 
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the one side Mn2+ bound sample, while in the two side Mn2+ bound sample, the signal intensity is 
significantly lowered (average is approximately 50%). Therefore, we can conclude that at low 
peptide concentrations, the MPP binds only to the outer leaflet while at high peptide 
concentrations the MPP is distributed in both the inner and outer leaflet of the bilayer. 
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Figure 8. The intensity of the Mn
2+
 bound sample (S) double normalized with respect to the unbound sample (S0) and the 
maximum lipid peak (S/S0)max. The shaded region shows the depth of MPP insertion in the bilayer for non gradient (Δψ = 0 
mV) and gradient (Δψ = -177 mV) LUVs. 
∆ψ = -177 mV ∆ψ = 0 mV
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Figure 9. 
13
C MAS NMR spectra illustrating the attenuation due to the PRE effect at low (P:L = 1:40) and high (P:L = 
1:10) peptide concentrations. The membrane schematics indicate the peptide location. a) One side Mn
2+
 bound 
CL/PC/PE vesicles with P:L = 1:40 red spectra, b) two side Mn
2+
 bound CL/PC/PE vesicles with P:L = 1:40 blue spectra, 
c) one side Mn
2+
 bound CL/PC/PE vesicles with P:L = 1:10 red spectra, and d) two side Mn
2+
 bound CL/PC/PE vesicles 
with P:L = 1:10 blue spectra. All spectra are overlaid with the unbound spectra (black) with the percent dephasing 
displayed for the peptide peaks. 
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P:L = 1:40 P:L = 1:10
Figure 10. High peptide concentration leads to distribution in both leaflets. At low P:L = 1:40 the MPP only binds to 
the outer leaflet because there is no change in the signal intensity. At high P:L = 1:10 the one side Mn
2+
 bound 
sample shows high signal intensity and the two side Mn
2+
 bound sample shows low signal intensity, indicative of 
distribution in both leaflets. 
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 From this data, it is also possible to estimate the MPP location in the bilayer (Figure 11). 
For P:L = 1:40, the normalized peptide signals are only compared to the two side Mn2+ bound 
lipid peaks. Because the MPP is only binding to the outer leaflet at this ratio, it is inaccurate to 
compare the intensity to the one side Mn2+ bound lipid peaks because only half of the lipids are 
experiencing PRE in this instance. Due to the fact that the MPP is fully dephased, all of the lipids 
must also be fully dephased to estimate the depth of insertion. Figure 10a shows that the MPP is 
inserted at approximately C1 - C2, at the top of the acyl chain in the interfacial region. This 
depth agrees with the electroporation model, which states that at low peptide-to-lipid ratios, the 
cationic side chains of the penetrating peptide interact with negatively charged phosphate 
headgroups on the outer leaflet.  
When the ratio is increased to P:L = 1:10, the peptide is distributed into both leaflets. For 
the one side Mn2+ bound sample, the peptide intensity is directly compared to the one side Mn2+ 
bound lipid signal. In this case, it is assumed that the MPP is distributed evenly on both leaflets 
and therefore, half of the peptide signal is retained, much like that of the lipid. For the same 
reason, the two side Mn2+ bound peptide intensities are compared to the two side Mn2+ bound 
lipid intensities. From the analysis shown in Figure 11b-c, it was concluded that the MPP is 
inserted symmetrically into both leaflets in the proximity of C2. Again, the MPP is still near the 
top of the acyl chain which further supports the electroporation theory. It is believed that anionic 
lipids, in this case cardiolipin, gather under the cationic peptides bound to the outer leaflet. At a 
certain threshold, this cationic peptide – anionic lipid system acts as a capacitor with a voltage 
negative enough to form transient pores, allowing the peptide to cross the bilayer where it can 
interact with negatively charged phosphate headgroups present on the inner leaflet. 
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Figure 11. At both high and low peptide concentrations, the MPP is bound near C2 of the lipid acyl 
chain. The intensity of the Mn
2+
 bound sample (S) double normalized with respect to the unbound 
sample (S0) and the maximum lipid peak (S/S0)max. The shaded region shows the depth of MPP 
insertion in the bilayer for (a) two side Mn
2+
 with P:L = 1:40, (b) one side Mn
2+
 with P:L = 1:10, and (c) 
two side Mn
2+
 with P:L = 1: 10. 
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Furthermore, the electroporation model provides an explanation as to how and why MPPs 
translocate the dense, hydrophobic portion of the inner mitochondrial membrane, which requires 
crossing an energy barrier higher than the peptide gains from crossing the potential difference of 
-180 mV present across the membrane. As charged peptides accumulate asymmetrically on the 
outer leaflet of the bilayer, a transmembrane electric field is induced that disrupts the local 
bilayer structure.7,9 In this study, the MPP is a short, four residue peptide with one arginine and 
one lysine residue, providing two cationic charges that can interact with phosphate headgroups of 
all three lipids: CL, PC, and PE. The electrostatic potential of a few MPPs binding to the outer 
leaflet is not strong enough for electroporation because the charge is reduced by counterions and 
the mean relative permittivity.8 An adequate amount of MPPs, (i.e. threshold concentration) need 
to bind nearby to provide the surface charge density to attract negatively charged phospholipids, 
which are diffusing on the inner leaflet in order to form a capacitor of sufficient voltage to permit 
passage through the formation of transient pores.8 The threshold for a sufficient voltage across a 
capacitor to form pores of electroporation ranges from -250 to -550 mV.8  
This indicates that the standard voltage observed across mitochondrial membranes is not 
enough to pull the peptides across, which is in agreement with our system where we observe no 
translocation (no peptide is reaching the inside of the vesicle). We have established that at high 
peptide-to-lipid ratios the MPP is pulled into the inner leaflet of the bilayer, but what happens in 
vivo? To answer this question, we examined two possibilities: (1) the MPP remains trapped in 
the IMM and does not translocate in vivo and (2) the curvature and salt concentration of our 
model system does not allow translocation of the MPP. 
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Free Energy Change of Peptide Translocation 
The transmembrane potential across mitochondrial membranes and the previously described 
model membrane is approximately -180 mV.18 An average bilayer thickness of our system was 
calculated to be 4.98 nm, based on literature values of bilayer thickness of cardiolipin,49 
phosphatidylcholine,50 and phosphatidylethanolamine.51 From this information, we calculated the 
electric field across the CL/PC/PE bilayer to be 3.6 × 107 V/m. We then calculated the driving 
force that this electric field exerts on the MPP using the following equation, 
 
where F is force, E is electric field across the CL/PC/PE bilayer, and q is the charge of the 
peptide. From this equation, we found that the force driving the MPP across the bilayer is F = 1.2 
× 10-11 J/m or 36 kJ/mol, considering that the peptide has two positively charged residues, Arg 
and Lys. 
 At high peptide-to-lipid ratios, we observe distribution of the peptide into both leaflets of 
the bilayer. It is interesting to consider the energy barriers that the MPP had to overcome in order 
to go from the outer leaflet, through the hydrophobic center of the bilayer, to the inner leaflet of 
the bilayer. We have analyzed this translocation as a three step process that is illustrated in 
Figure 11: (1) insertion into the outer leaflet at the membrane-water interface, (2) insertion into 
the hydrocarbon core, (3) insertion into the inner leaflet membrane-water interface (Figure 12). 
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(1)
(2)
(3)
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ΔGwif
-5 kJ/mol
ΔGtrans = ΔGwif - ΔGoct + ΔGwif
Δψ = -60 mV
ΔGelec = 12 kJ/mol
ΔGwif
-5 kJ/mol
ΔGwif
+10 kJ/mol
Δψ = -180 mV
ΔGelec = 36 kJ/mol
  
Figure 12. The energy profile associated with inserting the MPP into a plasma membrane (black) and the inner 
mitochondrial membrane (red). Step 1 inserts the MPP into the interfacial region of the outer leaflet. Step 2 inserts the 
MPP into the hydrocarbon core of the bilayer. Step 3 inserts the MPP into the interfacial region of the inner leaflet. 
Crossing the hydrocarbon core is associated with the highest energy barrier. The transmembrane potentials provide a 
driving translocating force. 
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The energy cost of inserting the MPP into the outer leaflet at the membrane-water 
interface (1) was analyzed using the Wimley-White interfacial hydrophobicity scale determined 
from  measurements of short peptides partitioning into zwitterionic phosphatidylcholine (POPC) 
vesicles.52-53  Therefore, this calculation reflects the free energy of insertion into zwitterionic 
vesicles. The equation used to estimate the free energy of insertion from water to interfacial (wif) 
region is as follows: 
 
 
Although the MPP in consideration has the amino acid sequence Cha – Arg – Cha – Lys, free 
energy of insertion values are not reported for any unnatural amino. Because Cha closely 
resembles Phe, this free energy value was substituted to give an estimate. Cha is more 
hydrophobic than Phe, so we would expect ∆Gwif to be slightly greater than the calculated value 
of -3.05 kJ/mol for the actual MPP sequence. However, we must also consider that each 
guanidinium ion can form up to five hydrogen bonds with the lipid phosphates or water.54 If we 
assume that each hydrogen bond can contribute a favorable free energy change of -2.09 kJ/mol,55 
then the free energy change could be as low as -5.14 kJ/mol. Therefore, we will assume that 
insertion of the MPP into the interfacial region is a favorable process. 
 For the second step, insertion of the MPP into the hydrocarbon core of the bilayer, we 
estimated the free energy barrier using the Wimley-White octanol hydrophobicity scale 
determined from measurements of short peptides partitioning from water into n-octanol (woct).56 
The equation used to estimate the energy of insertion into the hydrophobic core is as follows: 
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The additional value ∆GHbond must be included to account for the cost of partitioning a hydrogen 
bonded peptide backbone into the hydrophobic core.56 For our purposes, we have estimated this 
value to be +2.09 kJ/mol.56 Again, the free energy value for Phe was used in place of Cha to 
estimate the energy of insertion into the hydrophobic core. Because Cha is more hydrophobic 
than Phe, we expect the actual free energy of insertion to be more favorable than the estimated 
value of ∆Gwoct = 13.35 kJ/mol. 
 To ensure that this energy barrier to cross the hydrophobic core was reasonable, we 
compared the estimated ∆Gwoct to a similar calculation based on an experiment performed by the 
Kelley group to estimate lipophilicity.16 A modification of the shake-flask method previously 
described57 was used to determine the octanol partitioning of the MPP conjugated to thiazole 
orange and was reported as the partition coefficient, log P = -1.1.16 From this value the free 
energy from aqueous solution to octanol can be computed by the following equation: 
 
where R is the gas constant and T is temperature. This equation estimates the free energy of 
insertion to the hydrocarbon core to be 6.5 kJ/mol at physiological temperature, which is about 
half of the previous estimate of 13.35 kJ/mol. Some discrepancies are expected to arise from the 
Phe substitution for Cha and the conjugation of thiazole orange onto the MPP. Thiazole orange is 
a large, organic molecule and Cha is more hydrophobic than Phe, so it is logical that the free 
energy is much lower than the estimated value. Therefore, an average estimate for the energy 
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barrier that the MPP has to overcome to cross the hydrophobic core of the IMM is approximately 
10 kJ/mol. 
 Since we expect the interfacial region of the outer leaflet to be the same environment as 
the inner leaflet, the estimated value of ∆Gwif  = -5 kJ/mol will be the same for the third step as 
for the first step. If we examine the force across the plasma membrane, F = 12 kJ/mol (Figure 
12), this force is sufficient to pull the cationic peptide across the free energy barrier in the 
hydrocarbon core and overcome the stabilizing forces present in the interfacial region to enter the 
cytosol. From here, the peptide will be pinned down by the electric field outside the outer 
mitochondrial membrane. The OMM contains pore-like structures call porins, which all the 
passage of small peptides.18 The peptide can electrostatically interact with the anionic inner 
mitochondrial membrane. 
However, the process that occurs in the inner mitochondrial membrane is unclear. 
Because the inner mitochondrial membrane is anionic, rather than zwitterionic, the favorable free 
energy associated with the water – membrane interface will be lower than the calculated values 
(dotted red lines in Figure 12). This is due to the fact that the peptide experiences less charge – 
charge respulsion from a positively charged choline or ethanolamine headgroup. Although the 
force exerted by the transmembrane potential (36 kJ/mol) is about three times greater than that of 
the plasma membrane, it may not be enough to remove the peptide from the interfacial region 
and into the matrix because we do not know the depth of the wells. But, if the transmembrane 
gradient is the only force acting on the peptide, it is enough to pull the peptide over the high free 
energy barrier of the hydrocarbon core (we see distribution in both leaflets at high peptide 
concentration), it is likely enough to translocate from the interfacial region to the matrix. We can 
conclude that translocation of the peptide across the plasma and inner mitochondrial membrane 
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is a favorable process. Therefore, we probably do not observe translocation due to our system 
limitations. 
A viable reason that the MPP remains trapped in our model mitochondrial membranes is 
that the curvature strain, exacerbated by the presence of cardiolipin, and the salt concentration 
are preventing translocation. The curvature dependence on translocation of penetratin has been 
examined in other works with some conflicting results.58-59 One study showed that penetratin 
readily crosses GUVs (diameter >1 µm), but remain trapped in the lipid bilayer of LUVs 
(diameter 100 nm), indicating that curvature can dictate translocation.58 However, other work 
showed that in the presence of a transmembrane potential of -110 to -130 mV, penetratin was 
able to translocate across LUVs with a variety of lipid compositions, indicating that a 
transmembrane gradient allows the peptide to overcome the barrier of curvature strain.59 In our 
system we observe distribution of the MPP into both leaflets at high peptide concentration, but 
have not seen full translocation. 
The curvature strain present in LUVs has caused CPPs to become trapped in the bilayer,58 
and our system contains a lipid composition that lends itself to additional curvature. Cardiolipin, 
in particular, has been associated with stabilizing curvature in GUVs60-61 as well as LUVs.60 In 
the presence of local acidic pH, vesicles containing cardiolipin were shown to deform in such a 
way that mimicked cristae (Figure 13), the folds found biologically in mitochondria.60 It is 
possible that the acidic pH encapsulated in our model LUVs is acting as a local addition of acidic 
pH and is causing membrane deformations, similar to those shown in Figure 13. If this is the 
case, the curvature strain affecting our system would be much more substantial than the 
curvature normally encountered in LUVs and could be preventing translocation of the MPP. 
Although changing our membrane composition is not an option because cardiolipin plays such a 
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vital role in the IMM,18 the Kelley group has shown that the MPP is able to translocate across the 
plasma membrane in live cells in order to localize in the mitochondria.16 It would be of interest 
to determine how the MPP interacts with a model plasma membrane to see what insights this 
could provide for the mechanism of mitochondrial localization. 
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Figure 13. Cristae-like invaginations that are formed in 
GUVs with the local addition of HCl (100 mM, pH 1.6).
62 
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Another factor that could be influencing the translocation of the MPP is the high salt 
concentration, 300 mM, inside our LUVs to establish a transmembrane gradient of -180 mV. In 
the study that showed that CPPs can translocate across LUVs in the presence of a transmembrane 
potential, a different technique was used to establish the gradient.59 To construct a potential of -
110 to -130 mV, Terrone and coworkers used a buffer concentration of only 128 mM KCl and 
added of valinomycin, which selectively pumps K+ ions out from inside the LUV to make the 
inside negative.59 The membrane binding of peptides is extremely sensitive to salt concentration. 
In a study examining the thermodynamics of polylysine binding to lipid membranes, the free 
energy of binding decreased from -1.5 to -7 kcal/mol when the salt concentration was decreased 
from 500 mM to 50 mM.62 This makes binding to the inner leaflet in our system, which has a salt 
concentration of 300 mM inside more unfavorable than binding to the outer leaflet where the salt 
concentration is 10 mM. Because this may be inhibiting translocation, it would be interesting to 
construct a transmembrane potential across our LUVs using the valinomycin technique to 
examine MPP translocation. 
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4.0  CONCLUSIONS AND FUTURE WORK 
 
In conclusion, we have shown that the mitochondria-penetrating peptide with amino acid 
sequence Cha – Arg – Cha – Lys binds to model mitochondrial membranes in a fashion that 
supports the electroporation model, without disrupting the integrity of the membrane. At a low 
peptide-to-lipid ratio of P:L = 1:40, the MPP binds to the outer leaflet of the bilayer. At a high 
peptide-to-lipid ratio, P:L = 1:10, the concentration surpasses the threshold for electroporation 
and the peptide distributes in both the inner and outer leaflet.  
However, we have not observed the MPP reaching the interior of our vesicles. To test the 
hypothesis that cardiolipin in the LUVs is causing limiting membrane curvature, we are going to 
examine the interaction of the MPP with model plasma membranes, such as LUVs composed of 
phosphatidylcholine and phosphatidylserine. Also, to eliminate the possibility that our salt 
concentration is prohibiting translocation, we are considering forming LUVs with a 
transmembrane gradient induced by valinomycin. 
Furthermore, we would like to learn more about the forces stabilizing the MPP in the 
membrane – water interface to assess the depth of the energy wells in the IMM. Thus far, our 
work has indicated the possibility of a guanidinium – phosphate hydrogen bond because of the 
insertion depth of the peptide near the top of the acyl chains. 13C – 31P rotational echo double 
resonance (REDOR) experiment is an experiment that confirms the presence of this interaction. 
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REDOR is a powerful NMR tool that uses MAS and cross-polarization to measure the distance 
between two heteronuclei. Similar studies on CPPs have shown evidence of a guanidinium – 
phosphate hydrogen bond through this method which showed a distance of ~4 Ǻ between the Cδ 
of Arg and the phosphorus of the lipid phosphate headgroup (Figure 14).13,63-64 
 In order to determine the orientational constraints of MPPs within the bilayer, we are 
also considering 15N – 1H and 13C – 1H dipolar chemical shift correlation experiments. If the 
positively charged MPP side chains are non-covalently tethered to the negatively phospholipid 
headgroups, the Arg and Lys side chains would have higher order parameters near the cation due 
to restricted mobility.54 Consequently, the rest of the side chain and backbone would have lower 
order parameters and move more freely in the membrane.54 
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Figure 14. Image of the hydrogen bonding between the positively charged arginine side chain 
and the phospholipid headgroups.
66 
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Additionally, open questions remain about the assembly of peptide aggregates to induce 
translocation. Experiments to determine exactly how much the MPPs need to interact with one 
another to penetrate the bilayer can provide information on aggregation. In the proposed 
electroporation model, the peptides must act together to cause a significant positive charge on the 
outer leaflet. To examine this, we are considering 13C – 13C correlation experiments to determine 
if there are any aggregate structures forming amongst the peptides themselves. This experiment 
would be particularly interesting to perform at low peptide-to-lipid ratios to observe how the 
MPPs act together to build surface charge to further depolarize the membrane. 
Since we believe that the MPP is proceeding via an electroporation method, we are 
planning to perform more experiments to assess the nature of the transient pores. For example, 
the pores could span the entire length of the membrane, from the inner to outer leaflet, which 
would cause leakage of cell contents, thus decreasing the MPP utility for drug delivery. 
However, it is believed that these transient pores prevent leakage in some way. Perhaps the 
peptide is burrowing inside of the bilayer as the membrane repairs itself simultaneously. We can 
assess whether or not the MPP forms pores by performing a calcein leakage assay.65 Calcein is a 
fluorescent molecule, that when inside LUVs at a high enough concentration is self-quenching. If 
the lamellarity of the vesicles is comprised, the calcein is released and an increase in 
fluorescence is observed. Therefore, we can titrate a solution that has calcein encapsulated LUVs 
with the peptide. By using this experiment, we can determine if leakage occurs, and at what 
peptide concentration, based on when a fluorescence response is observed. 
Lastly, this study only examined one MPP with the amino acid sequence of Cha – Arg – 
Cha – Lys, and the Kelley group synthesized several different peptides that were able to localize 
in the mitochondria.16 As shown in Figure 14, several compounds with a +3 charge and a range 
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of lipophilicity were synthesized.16 Since different cell-penetrating peptides are reported to 
possess vastly different mechanisms of uptake2 it would be of interest to determine whether the 
same applies to mitochondria-penetrating peptides, or if one mechanism is universal. From the 
data presented in Figure 14, we would like to examine the mechanisms of compounds 2, 3, and 4 
and see how they compare to the electroporation model proposed for compound 5. 
Additionally, it has been proposed that the mechanism of internalization for cell 
penetrating peptides is cargo-dependent.66-67 A variety of therapeutic agents could be delivered to 
mitochondria via MPPs. For example, antioxidants to capture free radicals from the electron 
transport chain or nucleic acids for gene modulation would be tremendously useful.20 It would be 
interesting to study the different dynamics of model mitochondrial membranes if cargo is 
covalently attached to MPPs. Using model membranes and solid state NMR to determine the 
biological response of membranes would be a safe, conservative way to evaluate potential 
therapeutics. 
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Figure 15. The +3 peptide scaffolds and the quantitation of mitochondrial localization via calculation of Rr based on 
fluorescence response of fluorophore linked to the peptides, to (thiazole orange), compared to MitoTracker. 
Compounds 2, 3, 4, and 5 (the MPP examined in our work) exhibit high mitochondrial localization. Image adapted 
from Horton et al.
18 
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